Name | Number of supported studies | Average coverage | |
---|---|---|---|
melanocyte | 6 studies | 70% ± 23% | |
retinal pigment epithelial cell | 3 studies | 62% ± 15% |
Insufficient scRNA-seq data for expression of PMEL at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 98% | 129.33 | 320 / 328 | 95% | 3.03 | 169 / 178 |
liver | 98% | 199.88 | 221 / 226 | 91% | 20.66 | 371 / 406 |
uterus | 93% | 1553.86 | 158 / 170 | 92% | 8.49 | 422 / 459 |
ovary | 96% | 258.53 | 173 / 180 | 89% | 2.53 | 381 / 430 |
kidney | 93% | 127.13 | 83 / 89 | 89% | 6.53 | 804 / 901 |
thymus | 91% | 106.77 | 596 / 653 | 87% | 1.91 | 529 / 605 |
skin | 79% | 2829.35 | 1425 / 1809 | 99% | 7291.66 | 467 / 472 |
breast | 78% | 770.90 | 358 / 459 | 86% | 3.17 | 965 / 1118 |
stomach | 67% | 75.24 | 241 / 359 | 92% | 3.43 | 264 / 286 |
intestine | 55% | 88.96 | 528 / 966 | 95% | 3.99 | 502 / 527 |
lung | 59% | 59.89 | 342 / 578 | 90% | 2.85 | 1034 / 1155 |
prostate | 79% | 98.39 | 194 / 245 | 62% | 1.15 | 311 / 502 |
bladder | 48% | 56.76 | 10 / 21 | 91% | 4.24 | 461 / 504 |
esophagus | 35% | 31.46 | 500 / 1445 | 83% | 1.83 | 151 / 183 |
eye | 0% | 0 | 0 / 0 | 100% | 9400.26 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.43 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 93% | 2.55 | 42 / 45 |
adrenal gland | 44% | 38.00 | 114 / 258 | 20% | 0.96 | 46 / 230 |
adipose | 61% | 262.43 | 739 / 1204 | 0% | 0 | 0 / 0 |
spleen | 56% | 45.53 | 135 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 41% | 47.04 | 554 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 34% | 5.95 | 10 / 29 |
peripheral blood | 20% | 29.23 | 184 / 929 | 0% | 0 | 0 / 0 |
brain | 2% | 6.31 | 56 / 2642 | 10% | 0.31 | 70 / 705 |
heart | 11% | 9.16 | 98 / 861 | 0% | 0 | 0 / 0 |
muscle | 4% | 5.91 | 30 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042438 | Biological process | melanin biosynthetic process |
GO_0032438 | Biological process | melanosome organization |
GO_0048023 | Biological process | positive regulation of melanin biosynthetic process |
GO_0042470 | Cellular component | melanosome |
GO_0097487 | Cellular component | multivesicular body, internal vesicle |
GO_0033162 | Cellular component | melanosome membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0032585 | Cellular component | multivesicular body membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0033106 | Cellular component | cis-Golgi network membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0042802 | Molecular function | identical protein binding |
Gene name | PMEL |
Protein name | Premelanosome protein Melanocyte protein PMEL (ME20-M) (ME20M) (Melanocyte protein Pmel 17) (Melanocytes lineage-specific antigen GP100) (Melanoma-associated ME20 antigen) (P1) (P100) (Premelanosome protein) (Silver locus protein homolog) [Cleaved into: M-alpha (95 kDa melanocyte-specific secreted glycoprotein) (P26) (Secreted melanoma-associated ME20 antigen) (ME20-S) (ME20S); M-beta] Alternative protein PMEL |
Synonyms | PMEL17 SILV D12S53E |
Description | FUNCTION: Forms physiological amyloids that play a central role in melanosome morphogenesis and pigmentation. The maturation of unpigmented premelanosomes from stage I to II is marked by assembly of processed amyloidogenic fragments into parallel fibrillar sheets, which elongate the vesicle into a striated ellipsoidal shape. In pigmented stage III and IV melanosomes, the amyloid matrix serves as a platform where eumelanin precursors accumulate at high local concentrations for pigment formation. May prevent pigmentation-associated toxicity by sequestering toxic reaction intermediates of eumelanin biosynthesis pathway. .; FUNCTION: Represents a potent melanoma-specific antigen. Among melanoma non-mutated self-peptides, G9-154 (KTWGQYWQV), G9-209 (ITDQVPFSV) and G9-280 (YLEPGPVTA), appear to act as immunodominant common epitopes that stimulate anti-tumor immune response mediated by HLA-A-restricted cytotoxic T cells. . |
Accessions | ENST00000549404.5 P40967 ENST00000550464.5 [P40967-3] ENST00000546543.5 ENST00000552882.5 [P40967-1] ENST00000547137.5 ENST00000549418.5 ENST00000549233.2 F8VZV2 F8VYZ1 ENST00000449260.6 [P40967-2] F8VUB1 F8VZC6 H0YIJ2 ENST00000548803.5 L8ECD6 ENST00000550447.5 ENST00000548747.6 [P40967-1] F8W1D1 ENST00000548493.5 [P40967-1] F8VXH8 |